340 related articles for article (PubMed ID: 23556337)
21. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M
Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935
[TBL] [Abstract][Full Text] [Related]
22. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2008 Mar; 48(3):311-21. PubMed ID: 18187595
[TBL] [Abstract][Full Text] [Related]
23. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.
Werner D; Werner U; Meybaum A; Schmidt B; Umbreen S; Grosch A; Lestin HG; Graf B; Zolk O; Fromm MF
Clin Pharmacokinet; 2008; 47(5):323-32. PubMed ID: 18399713
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
Hedman M; Antikainen M; Holmberg C; Neuvonen M; Eichelbaum M; Kivistö KT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2006 Jun; 61(6):706-15. PubMed ID: 16722833
[TBL] [Abstract][Full Text] [Related]
25. Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients.
Yang GP; Yuan H; Tang B; Zhang W; Wang LS; Huang ZJ; Ou-Yang DS; Zhang GX; Zhou HH
Acta Pharmacol Sin; 2010 Mar; 31(3):382-6. PubMed ID: 20140004
[TBL] [Abstract][Full Text] [Related]
26. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
Lee HK; Hu M; Lui SSh; Ho CS; Wong CK; Tomlinson B
Pharmacogenomics; 2013 Aug; 14(11):1283-94. PubMed ID: 23930675
[TBL] [Abstract][Full Text] [Related]
27. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.
Keskitalo JE; Kurkinen KJ; Neuvoneni PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):457-61. PubMed ID: 19238649
[TBL] [Abstract][Full Text] [Related]
28. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
29. Effect of multidrug resistance gene-1 (ABCB1) polymorphisms on the single-dose pharmacokinetics of cloxacillin in healthy adult Chinese men.
Yin OQ; Tomlinson B; Chow MS
Clin Ther; 2009 May; 31(5):999-1006. PubMed ID: 19539100
[TBL] [Abstract][Full Text] [Related]
30. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
31. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
He J; Qiu Z; Li N; Yu Y; Lu Y; Han D; Li T; Zhao D; Sun W; Fang F; Zheng J; Fan H; Chen X
Eur J Clin Pharmacol; 2011 Jul; 67(7):701-7. PubMed ID: 21327909
[TBL] [Abstract][Full Text] [Related]
32. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
Niemi M; Schaeffeler E; Lang T; Fromm MF; Neuvonen M; Kyrklund C; Backman JT; Kerb R; Schwab M; Neuvonen PJ; Eichelbaum M; Kivistö KT
Pharmacogenetics; 2004 Jul; 14(7):429-40. PubMed ID: 15226675
[TBL] [Abstract][Full Text] [Related]
33. CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin.
Park JW; Kim JM; Lee HY; Noh J; Kim KA; Park JY
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890386
[TBL] [Abstract][Full Text] [Related]
34. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
[TBL] [Abstract][Full Text] [Related]
35. Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism.
Cho CK; Mo JY; Ko E; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 Feb; 47(2):95-110. PubMed ID: 38159179
[TBL] [Abstract][Full Text] [Related]
36. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
Pasanen MK; Backman JT; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2006 Jun; 62(6):409-15. PubMed ID: 16758257
[TBL] [Abstract][Full Text] [Related]
37. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2.
Ferrari M; Guasti L; Maresca A; Mirabile M; Contini S; Grandi AM; Marino F; Cosentino M
Eur J Clin Pharmacol; 2014 May; 70(5):539-47. PubMed ID: 24595600
[TBL] [Abstract][Full Text] [Related]
38. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
[TBL] [Abstract][Full Text] [Related]
39. Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin.
Choi CI; Lee YJ; Lee HI; Kim BH; Kim MJ; Jang CG; Bae JW; Lee SY
Xenobiotica; 2012 May; 42(5):496-501. PubMed ID: 22077103
[TBL] [Abstract][Full Text] [Related]
40. The effect of
Wang Y; Tian Y; Lv P; Chen L; Luo W; Jing X; Li H; Tan Z; Wang Y; Zhou H; Ouyang DS
Pharmazie; 2017 Jun; 72(6):365-368. PubMed ID: 29442027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
